Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce the following business update.
It has been a transformational year for Biocomposites. Against the backdrop of the pandemic and Brexit, Biocomposites’ lead product STIMULAN became the first calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft-tissue. The product is approved for mixing with vancomycin, gentamicin and tobramycin and can be placed directly into infected and non-infected sites. The global increase in infections caused by antibiotic resistant bacteria has required more targeted antibiotic treatment. STIMULAN® carries high concentrations of antibiotic to the point of infection at levels unachievable systemically – which lowers rates of reinfection, saves costs and improves patient outcomes – filling a major unmet medical need.